ASKG915 / Aosaikang Pharma - LARVOL DELTA

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: AskGene Pharma, Inc. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2024 ➔ Mar 2024

Enrollment open • Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=104 | Not yet recruiting | Sponsor: AskGene Pharma, Inc.

Metastases • New P1 trial • Oncology • Solid Tumor

Askgene cleared to enter clinic with anti-PD-1/IL-15 prodrug fusion molecule ASKG-915 (Bioworld) - "Askgene Pharma Inc. has received FDA clearance of its IND application to start a phase I study of ASKG-915, a novel and proprietary anti-PD-1/IL-15 prodrug fusion molecule for the treatment of cancer."

IND

"#AskGene Announces Submission of #IND to #FDA for #ASKG915 https://t.co/bj905abDD6" (@1stOncology)

"#AskGene Presents Latest Results on #ASKG315 and #ASKG915 at #SITC22 https://t.co/srKNP2Y4tE" (@1stOncology)

Oncology

ASKG915 - An Anti-PD-1 Antibody-IL-15 Prodrug Fusion Molecule with Enhanced Therapeutic Potentials (SITC 2022) - "To our knowledge, ASKG915 is the first anti-PD-1 antibody-IL-15 prodrug fusion molecule moving into clinical development. Ethics Approval The use of the animals in the studies have been approved by the ethics committees of the research contract organizations (CRO)."

Oncology • IFNG • IL15